메뉴 건너뛰기




Volumn 73, Issue 12, 2008, Pages 4345-4361

Structure-based drug design: Exploring the proper filling of apolar pockets at enzyme active sites

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; ARCHITECTURAL DESIGN; BINDING ENERGY; BIOCHEMICAL ENGINEERING; BIOCHEMISTRY; CHEMICAL WATER TREATMENT; CHEMOTHERAPY; COAGULATION; COMPUTER NETWORKS; DRUG DELIVERY; DRUG DOSAGE; DRUG THERAPY; EMPLOYMENT; ENZYME ACTIVITY; ENZYMES; FLOCCULATION; FLOW INTERACTIONS; FLUORINE; FOOD ADDITIVES; HEALTH; INDUSTRIAL ECONOMICS; METROPOLITAN AREA NETWORKS; NETWORK PROTOCOLS; POSITIVE IONS; TARGETS;

EID: 45249108005     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo800527n     Document Type: Review
Times cited : (91)

References (135)
  • 1
    • 0033915678 scopus 로고    scopus 로고
    • (a) Klebe, G. J. Mol. Med. 2000, 78, 269-281.
    • (2000) J. Mol. Med , vol.78 , pp. 269-281
    • Klebe, G.1
  • 15
    • 0242417008 scopus 로고    scopus 로고
    • Meyer, E. A.; Castellano, R. K.; Diederich, F. Angew. Chem., Int. Ed. 2003, 42, 1210-1250.
    • Meyer, E. A.; Castellano, R. K.; Diederich, F. Angew. Chem., Int. Ed. 2003, 42, 1210-1250.
  • 20
    • 0003825877 scopus 로고
    • The Royal Society of Chemistry: Cambridge
    • (a) Diederich, F. Cyclophanes; The Royal Society of Chemistry: Cambridge, 1991.
    • (1991) Cyclophanes
    • Diederich, F.1
  • 21
    • 0003461218 scopus 로고    scopus 로고
    • Vögtle, F. Ed, Elsevier-Pergamon: Oxford
    • (b) Comprehensive Supramolecular Chemistry; Vögtle, F. Ed.; Elsevier-Pergamon: Oxford, 1996; Vol. 2.
    • (1996) Comprehensive Supramolecular Chemistry , vol.2
  • 23
    • 3242887372 scopus 로고    scopus 로고
    • Gleiter, R, Hopf, H. Eds; Wiley-VCH: Weinheim, Germany
    • (d) Diederich, F. In Modern Cyclophane Chemistry; Gleiter, R., Hopf, H. Eds; Wiley-VCH: Weinheim, Germany, 2004.
    • (2004) Modern Cyclophane Chemistry
    • Diederich, F.1
  • 32
    • 45249115526 scopus 로고    scopus 로고
    • For a detailed discussion, see ref 11a, Chapter 7.4.3, pp 254-257
    • (b) For a detailed discussion, see ref 11a, Chapter 7.4.3, pp 254-257.
  • 36
    • 0033378391 scopus 로고    scopus 로고
    • For reviews on thrombin inhibitors, see: a
    • For reviews on thrombin inhibitors, see: (a) Rewinkel, J. B. M.; Adang, A. E. P. Curr. Pharm. Design 1999, 5 (12), 1043-1075.
    • (1999) Curr. Pharm. Design , vol.5 , Issue.12 , pp. 1043-1075
    • Rewinkel, J.B.M.1    Adang, A.E.P.2
  • 45
    • 45249099384 scopus 로고    scopus 로고
    • Schweizer, E. ETH Dissertation No. 16531, Zürich, 2006.
    • (c) Schweizer, E. ETH Dissertation No. 16531, Zürich, 2006.
  • 47
    • 38149070200 scopus 로고    scopus 로고
    • For another recent review on fluorine in medicinal chemistry, see
    • (b) For another recent review on fluorine in medicinal chemistry, see Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. Chem. Soc. Rev. 2008, 37, 320-330.
    • (2008) Chem. Soc. Rev , vol.37 , pp. 320-330
    • Purser, S.1    Moore, P.R.2    Swallow, S.3    Gouverneur, V.4
  • 59
    • 45249093044 scopus 로고    scopus 로고
    • CSD search: CSD version 5.29, November 2007, inclusive updates January 2008, containing about 440,000 entries. All searches were performed for structures with R factor <0.1 not distorted, no error, no partial disorder, excluding polymeric, powder, or organometallic compounds
    • CSD search: CSD version 5.29, November 2007, inclusive updates January 2008, containing about 440,000 entries. All searches were performed for structures with R factor <0.1 (not distorted, no error, no partial disorder), excluding polymeric, powder, or organometallic compounds.
  • 66
    • 36849028500 scopus 로고    scopus 로고
    • Wavefunction, Inc, Irvine
    • Spartan '06, Wavefunction, Inc.: Irvine, 2006.
    • (2006) Spartan '06
  • 70
  • 78
    • 34447317298 scopus 로고    scopus 로고
    • For Rivaroxaban (BAY 59-7939), an oral direct factor Xa inhibitor in phase III clinical trials, see: Agnelli, G.; Gallus, A.; Goldhaber, S. Z.; Haas, S.; Huisman, M. V.; Hull, R. D.; Kakkar, A. K.; Misselwitz, F.; Schellong, S. Circulation 2007, 116, 180-187.
    • (a) For Rivaroxaban (BAY 59-7939), an oral direct factor Xa inhibitor in phase III clinical trials, see: Agnelli, G.; Gallus, A.; Goldhaber, S. Z.; Haas, S.; Huisman, M. V.; Hull, R. D.; Kakkar, A. K.; Misselwitz, F.; Schellong, S. Circulation 2007, 116, 180-187.
  • 92
    • 45249085310 scopus 로고    scopus 로고
    • Schwarz, M. K. ETH Dissertation No. 10951, Zürich, 1994.
    • (b) Schwarz, M. K. ETH Dissertation No. 10951, Zürich, 1994.
  • 104
    • 33749256087 scopus 로고    scopus 로고
    • S-C interactions.
    • S-C interactions.
  • 106
    • 44349094544 scopus 로고    scopus 로고
    • We observed the turning away of larger substituents in cocrystal structures: Crane, C. M.; Hirsch, A. K. H.; Alphey, M. S.; Sgraja, T.; Lauw, S.; Illarionova, V.; Rohdich, F.; Eisenreich, W.; Hunter, W. N.; Bacher, A.; Diederich, F. ChemMedChem 2008, 3, 91-101.
    • We observed the turning away of larger substituents in cocrystal structures: Crane, C. M.; Hirsch, A. K. H.; Alphey, M. S.; Sgraja, T.; Lauw, S.; Illarionova, V.; Rohdich, F.; Eisenreich, W.; Hunter, W. N.; Bacher, A.; Diederich, F. ChemMedChem 2008, 3, 91-101.
  • 135


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.